Table 5.
Clinical efficacy of rabacfosadine in dogs.
| Disease | Treatment & | Subjects | Clinical efficacy* | Ref. |
|---|---|---|---|---|
| T-cell lymphoma | 1 mg/kg | Treatment-experienced dogs | 50% (2/4) | [95] |
| 1 mg/kg | Treatment-naive dogs | 43% (3/7) | [95] | |
| 1 mg/kg | Treatment-naive dogs | 50% (5/10) | [94] | |
| 0.82 mg/kg | Treatment-naive dogs | 50% (2/4) | [94] | |
| B-cell lymphoma | 1 mg/kg | Treatment-experienced dogs | 77% (24/31) | [96] |
| 0.82 mg/kg | Treatment-experienced dogs | 69% (11/16) | [96] | |
| 1 mg/kg | Treatment-naive dogs | 97% (29/30) | [94] | |
| 0.82 mg/kg | Treatment-naive dogs | 100% (11/11) | [94] | |
| Non-Hodgkin's lymphoma | 0.66 mg/kg | Treatment-naive dogs# | 67% (2/3) | [97] |
| 0.82 mg/kg | Treatment-naive dogs# | 50% (2/4) | [97] | |
&: A 30-minute intravenous infusion of rabacfosadine was administered once every 3 weeks for 5 doses
*: Clinical efficacy was defined by the overall response rate of dogs experiencing either partial responses or complete responses during the post-treatment period.
#: Previous treatment was allowable with ≥ three-week washouts from the most recent therapy.